載入中
NASDAQHealthcareMedical - Devices
最新資料
US$0.8101
−US$0.0006 · -0.07%
Bluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions. A key offering is their Symphony platform, an advanced technological system. This platform is composed of the Symphony analyzer, which skillfully orchestrates the processing of whole blood, the isolation of biomarkers, and the preparation of immunoassays using non-contact centrifugal force. It also includes the Symphony Cartridge, which comes pre-loaded with essential reagents and components. The company additionally provides the ALLEREYE diagnostic test, a convenient, on-site device for quickly identifying allergic conjunctivitis. Bluejay Diagnostics is also progressing with the development of Symphony IL-6 tests, intended for monitoring disease advancement in critical care environments. Furthermore, they are actively creating additional diagnostic tests for their Symphony platform, such as those aimed at detecting myocardial infarction (heart attack) and congestive heart failure. Bluejay Diagnostics, Inc. was founded in 2015 and is headquartered in Acton, Massachusetts.
前收盤價
US$0.8101
−US$0.0006 · -0.07%
盤前
US$0.82
+US$0.0099 · +1.22%
10月8日 上午5:34 ET
盤中時間採用ET。市場資料可能有所延遲。
Bluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions. A key offering is their Symphony platform, an advanced technological system. This platform is composed of the Symphony analyzer, which skillfully orchestrates the processing of whole blood, the isolation of biomarkers, and the preparation of immunoassays using non-contact centrifugal force. It also includes the Symphony Cartridge, which comes pre-loaded with essential reagents and components. The company additionally provides the ALLEREYE diagnostic test, a convenient, on-site device for quickly identifying allergic conjunctivitis. Bluejay Diagnostics is also progressing with the development of Symphony IL-6 tests, intended for monitoring disease advancement in critical care environments. Furthermore, they are actively creating additional diagnostic tests for their Symphony platform, such as those aimed at detecting myocardial infarction (heart attack) and congestive heart failure. Bluejay Diagnostics, Inc. was founded in 2015 and is headquartered in Acton, Massachusetts.
日內區間
目前US$0.8101
52週區間
目前US$0.8101
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
45
合理估值
情緒
56
多空交錯
風險
67
高風險
動能
19
強勢下行
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Bluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions. A key offering is their Symphony platform, an advanced technological system. This platform is composed of the Symphony analyzer, which skillfully orchestrates the processing of whole blood, the isolation of biomarkers, and the preparation of immunoassays using non-contact centrifugal force. It also includes the Symphony Cartridge, which comes pre-loaded with essential reagents and components. The company additionally provides the ALLEREYE diagnostic test, a convenient, on-site device for quickly identifying allergic conjunctivitis. Bluejay Diagnostics is also progressing with the development of Symphony IL-6 tests, intended for monitoring disease advancement in critical care environments. Furthermore, they are actively creating additional diagnostic tests for their Symphony platform, such as those aimed at detecting myocardial infarction (heart attack) and congestive heart failure. Bluejay Diagnostics, Inc. was founded in 2015 and is headquartered in Acton, Massachusetts.
日內區間
目前US$0.8101
52週區間
目前US$0.8101
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | — | — | 24.9萬 USD | — |
| 銷貨成本 | — | — | — | 20.01萬 USD | — |
| 毛利 | — | — | — | 4.89萬 USD | — |
| 研究與開發 | 304.64萬 USD | 347.17萬 USD | 571.46萬 USD | 415.22萬 USD | 114.8萬 USD |
| 銷售、一般及管理費用 | 390.65萬 USD | 369.79萬 USD | 459.66萬 USD | 521.45萬 USD | 208.22萬 USD |
| 營業費用 | 695.3萬 USD | 716.96萬 USD | 1031.12萬 USD | 936.67萬 USD | 323.02萬 USD |
| 利息收入 | 9.76萬 USD | 14.58萬 USD | 16.49萬 USD | 8.97萬 USD | 51.33萬 USD |
| 利息支出 | 839 USD | 82.3萬 USD | — | — | 36.75萬 USD |
| 折舊和攤銷 | 17.07萬 USD | 19.91萬 USD | 78.1萬 USD | 30.64萬 USD | 14.57萬 USD |
| 營業利益 | −695.3萬 USD | −716.96萬 USD | −1031.12萬 USD | −931.78萬 USD | −323.02萬 USD |
| 淨利 | −684.85萬 USD | −771.78萬 USD | −995.39萬 USD | −929.69萬 USD | −372.97萬 USD |
公司資料更新於 2026年10月8日。
近期已公布業績
近期已公布業績
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年1月29日 | 1:4 | — | — |
股票分割 | 2024年11月18日 | 1:50 | — | — |
股票分割 | 2024年6月20日 | 1:8 | — | — |
股票分割 | 2023年7月24日 | 1:20 | — | — |
已生效 2026年1月29日
1:4
已生效 2024年11月18日
1:50
已生效 2024年6月20日
1:8
已生效 2023年7月24日
1:20
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
